Date: 2015-05-12
Type of information: Nomination
Compound:
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 12, 2015, Adaptimmune, a clinical stage biotechnology company focused on the use of T-cell therapy to treat cancer, announced that it has strengthened its senior management team with the appointment of William (Will) Roberts as Vice President, Investor Relations. Mr. Roberts will lead the company’s investor communications strategies, along with involvement in wider communication programs and activities. Mr. Roberts brings over 20 years of investor relations, communications, and scientific experience in small, global mid-cap and large cap biotechnology companies to Adaptimmune. He spent ten years (2004-2014) with ViroPharma Incorporated (acquired by Shire in 2014) with responsibility for investor and media relations, patient and physician advocacy, certain branded communications regarding Cinryze® (C1 esterase inhibitor [human]) and other commercial products, and disease awareness, culminating in his service as Vice President, Corporate Communications. His record includes developing
award-winning communications programs such as ViroPharma\'s investor relations program which won IR Magazine\'s 2013 \'IR Professional of the Year – Small Cap\' and \'Grand Prix, Best Overall Investor Relations Program – Small Cap\' awards. Previously, Mr. Roberts spent 12 years (1992-2004) with MedImmune Inc. (acquired by AstraZeneca in 2007) in various scientific and investor relations roles of increasing responsibility. Most recently, he served as Vice President, Investor Relations and Corporate
Communications for Discovery Labs.
Financial terms:
Latest news:
